CLINICAL_TRIALS trial_result · 2023-01-23

Clinical Trial Update: Single Dose Intranasal Oxytocin and Cognitive Effects in Autism [Phase 2]

A Phase 2 trial evaluating single-dose intranasal oxytocin for cognitive effects in autism spectrum disorders has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: University of Minnesota | Conditions: Autism Spectrum Disorders | Phase 2 | Status: COMPLETED | Results posted: 2023-01-23